Health
ENHERTU® Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial in Patients with High-Risk Early Breast Cancer Following Neoadjuvant Therapy
TOKYO & BASKING RIDGE, N.J., September 29, 2025--ENHERTU Showed Statistically Significant Improvement in IDFS vs. T-DM1 in High-Risk Early Breast Cancer After Neoadjuvant Therapy in DESTINY-Breast05
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/05edf605bb9bd4ba0b82673e6a476d7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jE.1b3ITL.ZmgL_PcItc4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/05edf605bb9bd4ba0b82673e6a476d7c","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting","length":204,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results from the DESTINY-Breast05 and DESTINY-Breast11 trials will be presented at ESMO 2025 in a Presidential Symposium","length":120,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Plans for regulatory submissions are underway","length":45,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":369,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., September 29, 2025--(BUSINESS WIRE)--Positive topline results from a planned interim analysis of the DESTINY-Breast05 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) versus trastuzumab emtansine (T-DM1) in patients with HER2 positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence. This is the second positive phase 3 trial of ENHERTU in the HER2 positive early breast cancer setting following positive results from the DESTINY-Breast11 phase 3 neoadjuvant trial earlier this year.","length":754,"tagName":"p"},{"type":"text","content":"Overall survival (OS) was not mature at the time of this planned interim analysis and will be assessed at a subsequent analysis.","length":128,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by ...